FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
On December 17, the US Food and Drug Administration approved blinatumomab for 72- and 96-hour infusion durations to offer more flexibility for physicians and their patients.
In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
In Person Conference & ConventionApril 15, 2026 at 5:00 PM CDTPark Pl Blvd, St. Louis Park, MN, USADoubleTree by Hilton Hotel Minneapolis - Park Place, St. Louis Park
